



## The efficacy of CUTICERIN® with or without a Regenerative Epithelial Suspension (RES™), on donor site pigmentation in children: The DRESSing Trial Protocol

Anjana Bairagi<sup>1,2,3</sup>, Bronwyn Griffin<sup>1,2,3</sup>, Zephanie Tyack<sup>1,4,5</sup>, Steven M McPhail<sup>4,5</sup>, Dimitrios Vagenas<sup>6</sup>, Craig A McBride<sup>1,2,7</sup>, Roy Kimble<sup>1,2,3,7</sup>

<sup>1</sup>Centre for Children's Burns and Trauma Research, <sup>2</sup>Pegg Leditschke Children's Burns Centre, <sup>3</sup>School of Nursing & Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology <sup>4</sup>School of Public Health and Social Work & Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology, <sup>5</sup>Centre for Functioning and Health Research, Metro South Health, Brisbane, <sup>6</sup>Research Methods Group & Institute of Health and Biomedical Innovation IHBI, Queensland University of Technology, <sup>7</sup>Faculty of Medicine, University of Queensland

### Introduction:

Abnormal colour (dyspigmentation) of donor site wounds (DSW) are easily identified and cause much distress in a child. The **Regenerative Epithelial Suspension (RES™)** prepared with RECELL® Autologous Cell Harvesting Device, comprises the **fundamental cellular components** for human melanogenesis. **Improved** colour in patients with pigmentation disorders was demonstrated using RES™. However, the **effectiveness of RES™** in paediatric DSW is unknown. The **DRESSing trial** aims to evaluate the efficacy of RES™ for DSW management in children.

### Method:

- *Study Design:* Two-arm, parallel group, single-centre randomised trial.
- *Eligibility:* Children (age < 16 years, n=40) requiring an autograft after an acute partial thickness burn.
- *Primary outcome:* Donor site scar colour at 12 months after autograft.
- *Secondary Outcomes:* Donor site re-epithelialisation time, pain, itch, scar severity, health-related quality of life, treatment satisfaction, dressing application ease and healthcare resource utilisation

### Conclusion:

Paediatric DSW dyspigmentation affects the quality of life for burn survivors, especially children. This trial will add to the body of evidence regarding the efficacy of cell-based therapies in managing abnormal colour of autograft donor site scars.

### Contact:

Dr Anjana Bairagi  
Centre for Children's Burns & Trauma Research

@anjana.bairagi

bairagi@qut.edu.au




Figure 1. CONSORT Flow diagram.

# Can RES™ improve the colour of autograft donor sites in children?

